H.U. Group Holdings, Inc. announced that Fujirebio Diagnostics AB and Beckman Coulter, Inc. have concluded an agreement to expand their existing partnership in the field of neurodegenerative diseases. In 2023, Fujirebio and Beckman Coulter entered into a collaboration agreement2 to establish a partnership for the development, manufacturing, and clinical adoption of neurodegenerative disease assays, including Alzheimer's disease. Today's announcement extends this partnership, including a pTau217 plasma assay and a Beta-Amyloid 1-42 plasma assay.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,416 JPY | +0.86% | +3.85% | -9.29% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.29% | 872M | |
-17.89% | 8.25B | |
+39.20% | 3.57B | |
-39.11% | 2.46B | |
-8.06% | 2.46B | |
-7.35% | 2.38B | |
-12.61% | 1.81B | |
-19.01% | 1.55B | |
-40.66% | 1.21B | |
+7.56% | 1.11B |
- Stock Market
- Equities
- 4544 Stock
- News H.U. Group Holdings, Inc.
- Fujirebio and Beckman Coulter Expand Partnership to Develop Patient-Friendly, Blood-Based Neurodegenerative Disease Diagnostics